Analyst Ratings for Kinnate Biopharma (KNTE) [Buys]
KNTE Rating Summary
KNTE Price Target Summary
- Highest: $4.00 (Piper Sandler)
- Lowest: $2.00 (Wedbush)
- Average: $2.65
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$2.65 (-0.1%)
* Over Last 12-Mos
Rating Score: 3.8 / 10
Percentile Rank: 36%
Avg. $ Target:
$2.65 (-0.1%)
* Over Last 12-Mos
Rating Score: 3.8 / 10
Percentile Rank: 36%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/27/2021 | Jefferies » Updated 9/19/2023 |
Roger Song | New Coverage | Buy (N/A) |
2.00 (31.00) |
23.15 (2.65) |
-88.55% | Details |
| 12/28/2020 | Leerink Partners | Andrew Berens | New Coverage | Outperform (N/A) |
52.00 (N/A) |
38.00 (2.65) |
-93.03% | Details |
 |
||||||||
